問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

趙恆勝

Recruiting

List

62Cases

2019-04-01 - 2022-12-31

Phase II

A Phase 2 trial of durvalumab (MEDI4736) and tremelimumab with chemotherapy in metastatic EGFR mutant non-squamous non-small cell lung cancer (NSCLC) following progression on EGFR Tyrosine Kinase Inhibitors (TKIs)

  • Condition/Disease

    non-squamous non-small cell lung cancer

  • Test Drug

    Durvalumab、Tremelimumab

Participate Sites
8Sites

Recruiting8Sites

夏德椿
China Medical University Hospital

Division of General Internal Medicine

2020-05-01 - 2025-05-31

Phase III

A Randomized Phase 3 Multicenter Open-label Study to Compare the Efficacy of TAK-788 as First-line Treatment Versus Platinum-Based Chemotherapy in Patients With Non–Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations

  • Condition/Disease

    A Randomized Phase 3 Multicenter Open-label Study to Compare the Efficacy of TAK-788 as First-line Treatment Versus Platinum-Based Chemotherapy in Patients With Non–Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations

  • Test Drug

    TAK-788 (AP32788)

Participate Sites
9Sites

Recruiting9Sites

2022-10-01 - 2024-12-12

Phase I/II

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2020-03-01 - 2022-12-30

Phase I

A Phase 1, Open-Label, Multicenter Study to Assess the Safety and Tolerability of mRNA-5671/V941 as a Monotherapy and in Combination With Pembrolizumab in Participants With KRAS Mutant Advanced or Metastatic Non-Small Cell Lung Cancer, Colorectal Cancer or Pancreatic Adenocarcinoma

  • Condition/Disease

    Advanced/Metastatic solid tumors

  • Test Drug

    V941 (mRNA-5671)/ Pembrolizumab

Participate Sites
3Sites

Recruiting3Sites

2021-07-15 - 2025-05-01

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2019-06-01 - 2021-09-28

Phase II

A Multicenter, Double Blind, Randomized, Controlled Study of M7824 With Concurrent Chemoradiation Followed by M7824 Versus Concurrent Chemoradiation Plus Placebo Followed by Durvalumab in Participants With Unresectable Stage III Non-small Cell Lung Cancer

  • Condition/Disease

    Non-small Cell Lung Cancer

  • Test Drug

    M7824

Participate Sites
5Sites

Recruiting5Sites

2018-12-15 - 2022-09-27

Phase II

An Adaptive Phase III, Multicenter, Randomized, Open-Label, Controlled Study of M7824 (Bintrafusp Alfa) Versus Pembrolizumab as a First-line Treatment in Patients With PD-L1 Expressing Advanced Non-small Cell Lung Cancer

  • Condition/Disease

    Non-small Cell Lung Cancer

  • Test Drug

    M7824

Participate Sites
4Sites

Not yet recruiting1Sites

Recruiting3Sites

沈佳儀
Taipei Veterans General Hospital

Division of Thoracic Medicine

2018-07-18 - 2021-08-31

Phase II

A Phase II Single-arm Trial to Investigate Tepotinib in Advanced (Locally Advanced or Metastatic) Non-small Cell Lung Cancer With METex14 Skipping Alterations or MET Amplification (VISION)

  • Condition/Disease

    Non-small Cell Lung Cancer

  • Test Drug

    tepotinib

Participate Sites
6Sites

Recruiting2Sites

Terminated4Sites

陳育民
Taipei Veterans General Hospital

Division of Thoracic Medicine

2020-09-15 - 2024-03-29

Phase III

A Phase III, Randomized, Double-blind Study to Assess the Efficacy and Safety of Lazertinib Versus Gefitinib as the First-line Treatment in Patients With Epidermal Growth Factor Receptor Sensitizing Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer

  • Condition/Disease

    Epidermal Growth Factor Receptor Sensitizing Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer

  • Test Drug

    Lazertinib

Participate Sites
7Sites

Recruiting6Sites

Terminated1Sites

2022-05-01 - 2023-02-23

Others

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

1 3 4 5 6 7
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB